Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Inflectra to be first 'substitutable' biosimilar in Australia

This article was originally published in SRA

Executive Summary

Australia's Pharmaceutical Benefits Advisory Committee has recommended that Hospira's biosimilar Inflectra (infliximab) - which has only just been approved as the country's first biosimilar monoclonal antibody - should be listed on the Pharmaceutical Benefits Scheme1,2. And in a highly controversial move, the PBAC has also said that Inflectra should be 'a'-flagged, meaning that it can be substituted by pharmacists for the originator drug, Johnson & Johnson's Remicade.

Advertisement

Related Content

Australia's Biosimilar Substitution Policy Under Fire As Etanercept Product Is 'A'-Flagged

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS078837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel